Below is a compact, citation-backed reference pack focused on companies + values for the Scleral Lens Market, plus the market numbers and the sections you requested. I prioritized sources that report market size or company financials; where firms do not report scleral-only revenues I call that out and give the closest available company value (contact-lens / vision segment sales or public/company estimates).

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Scleral Lens market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Scleral Lens market.

Read complete report at: https://www.thebrainyinsights.com/report/scleral-lens-market-14706

Quick market snapshot (values)

• market size USD 330.75M (2025) → USD 538.76M (2030) (CAGR ~10.25%).

• market size USD 360.2M (2025) → USD 781.5M (2032) (CAGR ~11.7%).

Load-bearing conclusion: global scleral market in the mid-hundreds of millions USD today, with multi-year forecasts ranging from mid-single to low-double digit CAGRs depending on scope. Use a single publisher when you need to cite one authoritative figure.

Major companies (who’s cited) — with closest available values / financial context

Important: Most large ophthalmic firms don’t publish “scleral-only” revenues. Below I give (A) the company name, (B) whether scleral revenue is reported (usually no), and (C) the closest public value (segment / company revenue or credible estimate) with a citation.

1. Bausch + Lomb (Bausch Health) — scleral revenue not broken out.

   • Closest public value: Bausch + Lomb segment revenue: USD 4.79B (full-year 2024) (Bausch Health reporting for the Bausch + Lomb segment).

2. CooperVision / CooperCompanies — scleral revenue not broken out (group reports contact-lens revenue).

   • Closest public value: CooperCompanies total revenue ~USD 1.02B (Q4 2024 quarter) / annual trends — CooperVision segment ~USD 621–670M (quarterly segment figures reported in FY2024 releases). 

3. EssilorLuxottica — does not report scleral-only numbers; contact/vision portfolio included in larger optics/medical group.

   • Closest public value: Group revenue EUR 26.5B (FY 2024) — gives scale of company (scleral part is a tiny niche inside this). 

4. Menicon — specialty contact-lens company (reports product sales).

   • Reported: Menicon publishes product sales and geographic breakdowns (contact-lens & lens-care product sales shown in investor materials). Example: product / overseas sales figures appear in Menicon filings (see integrated/financial reports). Menicon reports product sales figures in its annual/IR materials (see PDF). SynergEyes (specialized scleral / hybrid lens company) — private / not broken out in public filings.

5. • Indicator: SynergEyes has raised ~USD 48.4M total funding (Tracxn profile) — useful scale proxy for private specialist vendor. No public annual revenue disclosure found in standard filings.

6. Visionary Optics (small specialty lab) — private; third-party estimate: estimated revenue ≈ USD 5M / year (Growjo estimate). Use cautiously — it’s a market estimate, not audited disclosure.

7. Specialty labs & smaller custom manufacturers (SynergEyes, X-Cel, Art Optical, Blanchard, Valley Contax, Alden Optical, Custom Craft, Contamac — materials supplier) — company-level scleral sales generally not published; many are private labs or part of larger groups. Where available, use lab/company investor materials or vendor product lists for evidence. Contamac is a materials supplier referenced in reports. 

Recent developments (short bullets)

• Rising clinical adoption for keratoconus, severe dry eye and post-surgical irregularities; new materials (high Dk) and digital fitting workflows expanding adoption.

• Growth in mini-scleral designs and specialty lab digitalization (imaging → CAD → lathe/custom manufacture).

Drivers / Restraints / Regional split (high level)

• Drivers: higher diagnosis rates of corneal disease, improved materials, greater clinician training, therapeutic uses (dry eye).

• Restraints: higher price, fitting complexity, limited reimbursement, and limited published company-level sales data for the lens type. 

• Regional: North America largest share (established specialist network); Asia-Pacific fastest growth (rising diagnostics and eye-care access). 

Emerging trends / Use cases / Challenges / Opportunities (short)

• Trends: mini-sclerals, therapeutic scleral use (dry eye), CAD/CAM + digital labs.

• Top use cases: keratoconus, severe/ocular surface disease, post-surgical corneal irregularity.

• Challenges: clinician training shortage, cost sensitivity, fragmented lab supply.

• Opportunities: training programs, APAC expansion, subscription/replacement service models, and faster mini-scleral workflows.

Short recommendations / next steps (pick one)

• If you want a company table (CSV) I can compile: company → company type (manufacturer / lab / supplier) → closest available public value or estimate → source link. (This will list ~20–30 vendors and mark whether the value is a reported revenue or an estimate.)

• If you want company revenue estimates for up to 6 public companies (e.g., Bausch + Lomb, CooperVision, Essilor) I can triangulate contact-lens / vision segment revenues and clearly flag which numbers are scleral estimates versus reported segment revenues. (This requires pulling multiple company filings & analyst notes; I can do that now.)

Tell me which deliverable you prefer: (A) CSV of vendors + sources, (B) company revenue table for up to 6 named public companies, or (C) one-page PPTX summary (market snapshot + top vendors + 5-year chart). I’ll generate the requested file and include direct citations.

If you’d like I can start immediately with A: CSV vendor table + sources (most useful when many vendors are private and values are sparse).